Asmont

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asmont

What is Asmont (Montelukast)? An Overview

Asmont is a synthetic, orally active prescription medicine used for long-term control of inflammatory respiratory conditions. Its active component is Montelukast (as Montelukast Sodium).

Property Description
Active ingredient Montelukast (as Montelukast Sodium)
Form Tablet (film-coated, chewable), oral granules
Pharmacological class Leukotriene Receptor Antagonist (LTRA)
Common purpose Prophylaxis and chronic management
Origin Synthetic chemical compound

What Type of Medicine is Asmont (Montelukast)?

Asmont is a single-ingredient medicinal preparation classified as a Leukotriene Receptor Antagonist (LTRA), a specialized pharmacological class of leukotriene modifiers. The active substance, Montelukast, is a synthetic chemical entity recognized by pharmacological studies for its high selectivity and efficacy in antagonizing the leukotriene pathway. This confirms that the medication is designed to specifically target systemic chemical signals involved in inflammation, differentiating its mechanism from that of general antihistamines or inhaled medications.

Its classification as an LTRA signifies that Asmont is clinically recognized for modifying the body's inflammatory response by blocking a certain chemical pathway. This mechanism places it distinctly outside the category of quick-relief inhalers, positioning it as a foundational agent for chronic management.


Composition and Available Forms

The core composition of Asmont features Montelukast Sodium along with pharmaceutical excipients necessary for the drug's oral delivery. The medication is available in several dosage forms, primarily including the standard film-coated tablet, the chewable tablet, and oral granules. The oral administration route facilitates sustained, systemic action, which is a key feature of the Montelukast formulation.

The availability of multiple forms, such as the chewable tablet and granules, addresses a common need in patient care by accommodating different age groups and compliance requirements. For instance, the granules provide an easy method for administering the drug to young children, a patient group that often requires chronic preventative care.


How Does Asmont Generally Help (General Purpose)?

The general purpose of Asmont is to serve as a preventative treatment that targets the underlying causes of chronic airway inflammation. The drug exerts its effect by selectively blocking the action of leukotrienes, which are potent inflammatory chemicals released in the lungs and nasal passages during allergic or irritant responses.

By consistently reducing the power of these inflammatory signals, Asmont helps maintain open, stable airways and less congested nasal passages. This action supports the long-term control of associated chronic inflammatory responses, establishing the medication as a foundational part of preventative care, not immediate relief. This preventative capability is why it is typically prescribed for daily, long-term administration.

Regulatory References

  1. DailyMed: Montelukast Sodium
  2. NIH StatPearls: Montelukast

What side effects are possible with Asmont?

Possible Side Effects and Safety Information

The official safety profile for Asmont (Montelukast) outlines adverse reactions classified by frequency and system-organ class, strictly based on regulatory documentation. The most frequently documented adverse events relate to infections and common systemic symptoms.


Frequency-Classified Adverse Reactions

Adverse reactions are categorized according to regulatory standards:

  • Very Common (ge 1/10): Upper respiratory infection.
  • Common (ge 1/100 to < 1/10): Headache, abdominal pain, fever (pyrexia), diarrhea, nausea, vomiting, and rash.
  • Uncommon to Very Rare: These categories include hypersensitivity reactions, sleep disturbances (insomnia, dream abnormalities), aggression, depression, dizziness, dry mouth, epistaxis, and elevated liver enzymes.

Serious Adverse Reactions and Safety Constraints

The FDA has mandated a Boxed Warning regarding the risk of serious neuropsychiatric events, including agitation, anxiety, depression, hallucinations, and suicidal thoughts or behavior. Rare but serious systemic reactions reported include cases of hepatitis and vasculitis consistent with Churg-Strauss syndrome.

Safety Restrictions: Asmont is not indicated for the reversal of bronchospasm during acute asthma attacks. It should not be abruptly substituted for inhaled or oral corticosteroids. Patients with phenylketonuria (PKU) should note that the chewable tablet form contains phenylalanine.

This regulatory information structures the understanding of the medicine's risk profile by detailing the scope and severity of documented effects across different physiological systems.

Overdose and Emergency Response

Overdose: Asmont (Montelukast)

This information describes the official overdose profile as documented in government regulatory sources, and not intended as clinical advice.

Documented Overdose Manifestations

In cases of acute, high-dose ingestion of Asmont (montelukast), the majority of reports indicate no adverse effects. When symptoms do occur, the documented clinical manifestations are generally mild and may include:

  • Abdominal pain
  • Somnolence (drowsiness)
  • Vomiting
  • Thirst
  • Headache
  • Psychomotor hyperactivity (restlessness/agitation)

Specifically in the pediatric population, the most common reported symptoms are abdominal pain, somnolence, and psychomotor hyperactivity.

Immediate Emergency Action

Urgent medical attention must be sought immediately in the event of any suspected overdose. Contact a Poison Control Center or national emergency services for guidance.

  • No specific antidote is available for montelukast overdose.
  • Management consists of general supportive measures and close clinical observation of the patient's condition.
  • Due to the drug's high protein binding, regulatory information states that measures such as hemodialysis are unlikely to be effective for drug removal.

Therapeutic Uses of Asmont

What Asmont Treats: Main Uses and Benefits

The role of Asmont (Montelukast) plays a role in managing chronic conditions marked by symptoms related to inflammatory or irritative states in the airways, and is considered relevant for easing symptoms that interfere with daily functioning. The medication is commonly used to help with these therapeutic domains.

Asmont is utilized as a long-term management option for chronic conditions presenting with disruptive symptom manifestations. The key therapeutic domains include the long-term symptomatic management of persistent asthma symptoms; the symptomatic relief of seasonal and perennial allergic rhinitis; and the supportive management of breathing difficulties related to exercise (EIB).

For patients seeking support during conditions involving episodic or fluctuating manifestations, Asmont assists with maintaining functional stability and may assist with easing the overall symptom burden during periods of heightened symptoms. This preventative approach may support patients during difficult episodes by easing distress.

“The application of this medication is relevant for managing conditions characterized by symptoms related to inflammatory or irritative states.”

Quick Fact: Management for Inflammatory Airway Symptoms

Asmont is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic support for recurrent issues like wheezing, chest tightness, chronic coughing, and nasal congestion, which frequently interfere with daily functioning.

Regulatory References

  1. official DailyMed labeling information

Eligibility and Restrictions for Use

Who Can and Cannot Use Asmont?

The population eligible to use Asmont (Montelukast) is strictly defined by regulatory authorities based on age, indication, and clinical history. The medicine is primarily approved for long-term use in adults and children for specific conditions.


Contraindications and Prohibited Use

Asmont must not be used in the following populations:

  • Patients with a known hypersensitivity (allergic reaction) to Montelukast or any component of the formulation.
  • Treatment of acute asthma attacks (Asmont is not indicated as a rescue therapy for sudden bronchospasm).

Eligibility by Age and Condition

Eligibility depends on the specific condition being treated, with defined minimum age thresholds:

Condition Minimum Age for Use
Chronic Asthma 12 months
Seasonal Allergic Rhinitis (SAR) 2 years
Perennial Allergic Rhinitis (PAR) 6 months
Exercise-Induced Bronchoconstriction (EIB) 6 years

Safety and effectiveness have not been established in children younger than the specified minimum age for each indication.


Special Populations

  • Hepatic/Renal Impairment: No dosage adjustment is typically required for patients with renal impairment or mild-to-moderate hepatic impairment. Use in severe hepatic impairment is not established.
  • Pregnancy and Lactation: Available data do not establish a drug-associated risk during pregnancy or a significant risk to the breastfed infant, though use should be considered carefully.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Asmont (Montelukast) is based on specific changes in drug exposure documented in regulatory studies. No medicinal products are formally listed as contraindicated combinations with Montelukast in primary regulatory documentation.


Documented Pharmacokinetic Interactions

Interactions primarily involve drugs that affect the Cytochrome P450 (CYP) enzyme systems, which metabolize Montelukast. The most significant documented interaction is with Gemfibrozil (a potent CYP 2C8 inhibitor), which increases the systemic exposure (AUC) of Montelukast by approximately 4.4-fold.

Conversely, co-administration with strong CYP enzyme inducers, such as Phenobarbital or Rifampicin, may lead to a potential decrease in the systemic exposure of Montelukast. Regulatory data shows that Montelukast does not significantly alter the pharmacokinetics of many other co-administered medicines, including Theophylline, Warfarin, and Digoxin.


Food and Population-Specific Considerations

Category Regulatory Notes
Food Interaction The 10-mg film-coated and 5-mg chewable tablets may be administered without regard to the time of food ingestion.
Pediatric Caution Caution should be exercised, particularly in children, when Montelukast is co-administered with CYP enzyme inducers.

The official labeling also states that Montelukast should not be used concomitantly with other products containing the same active ingredient, montelukast.

Mechanism of Action

Molecular Blockade of the Cysteinyl Leukotriene Pathway

The primary mechanism of Asmont (Montelukast) involves the selective antagonism of the Cysteinyl Leukotriene Receptor type 1 (CysLT1). This action directly prevents the potent inflammatory mediators LTC4, LTD4, and LTE4 from activating the receptor, thereby interrupting the signaling cascade that mediates airway smooth muscle contraction and inflammatory cell activity.


️ Regulation of Smooth Muscle Tone and Edema

By blocking the CysLT1 receptor, the drug suppresses the signaling that causes airway smooth muscle cells to contract, which results in the maintenance of airway caliber. This mechanism also acts on the vascular system to reduce the leukotriene-mediated increase in vascular permeability, thereby mitigating edema (swelling) of the respiratory mucosa and contributing to the stability of physiological function.


Sustained Dampening of Inflammatory Cell Activity

The mechanism extends beyond muscle tone to modulate the underlying inflammatory signaling by reducing the activation and infiltration of pro-inflammatory cells, notably eosinophils, into the respiratory tissues. This continuous biological control over a crucial inflammatory pathway sustains a dampening effect on chronic inflammatory signaling kinetics, distinguishing its mechanism from those required for rapid counteraction of acute physiological events.

Dosage and Administration Information

How Asmont (Montelukast) is Used: Official Administration Guidelines

Asmont is an orally administered medication designed for long-term control, following strict usage guidelines. The method, dose, and frequency of use are standardized across different age groups and indications.


Official Routes and Dosage Forms

Administration Route Available Forms
Oral Film-Coated Tablets (10 mg), Chewable Tablets (5 mg and 4 mg), Oral Granules (4 mg)

Standard Dosing and Frequency

The primary regimen for chronic management is once daily, typically taken in the evening for asthma and/or concurrent allergic rhinitis. Dosing is standardized by age:

  • Adults and Adolescents (ge 15 years): 10 mg once daily.
  • Children (6 to 14 years): 5 mg once daily.
  • Children (6 months to 5 years): 4 mg once daily.

For the prevention of Exercise-Induced Bronchoconstriction (EIB), 10 mg is taken as a single dose at least 2 hours before exercise. A patient already on the daily dose must not take an additional dose for EIB prevention within 24 hours of the previous one.


Administration Context and Special Instructions

  • Food Intake: Asmont can be taken with or without food.
  • Chewable Tablets: These must be chewed thoroughly before swallowing.
  • Oral Granules: Granules may be administered directly or mixed with 5 mL of cold or room-temperature liquid (formula/breast milk) or soft foods (applesauce, carrots, rice, ice cream). The entire mixture must be administered within 15 minutes of opening the packet.
  • Population Adjustments: No dosage adjustment is required for older adults or patients with renal or mild-to-moderate hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asmont (Montelukast)

Evidence for Use in Chronic/Persistent Asthma

The research base for Asmont in asthma primarily consists of Randomized Controlled Trials (RCTs) and scientific meta-analyses involving both adults and children from 12 months of age. These studies were used in research exploring how symptoms change over time for individuals with mild to moderate persistent asthma. Researchers monitored outcomes related to physical discomfort and outcomes reflecting daily functioning, such as changes in lung function measures (like FEV1), asthma symptom scores, and the documented frequency of exacerbations (periods of heightened symptom activity).

Findings describe patterns observed in the studies where the drug was evaluated as a single therapy or as an add-on to existing treatments. Studies reported measurements of changes in exacerbation rates compared to baseline or a control group. The research also explored outcomes related to the need for rescue medication and Quality of Life (QoL) metrics. Data for certain groups, such as those with very severe asthma, remain insufficient, and the long-term effects are not fully established beyond one year.

Evidence for Symptom Relief in Allergic Rhinitis

Asmont was studied for its relevance in trials assessing short-term or episodic symptom patterns related to both Seasonal and Perennial Allergic Rhinitis. The main research consists of short-term RCTs that involved adults and children. These studies focused on outcomes linked to inflammatory or irritative states. Researchers monitored outcomes related to physical discomfort using Total Nasal Symptom Scores and patient-reported outcomes describing perceived discomfort on Quality of Life (QoL) scales.

Most studies exploring short-term symptom changes in allergic rhinitis have follow-up durations that were limited, often to six weeks or less. The evidence quality varies across studies, and some regulatory bodies have described the drug’s role for patients who have inadequate response or intolerance to alternative standard therapies.

Evidence for Preventing Exercise-Induced Bronchoconstriction (EIB)

Research examining temporary physiological imbalance related to EIB primarily involved specific Randomized Controlled Trials using standardized, laboratory-based exercise challenge testing. The core measurement monitored was the change in lung function (FEV1) immediately after an exercise challenge. The research describes that studies monitored the drug's role in the preventative context against the post-exercise drop in lung function. Studies explored both the effect of a single dose and the sustained pattern of response over several weeks of daily dosing.

Limitations and Areas of Research Uncertainty

Scientific reviews have described that findings for some outcomes varied when compared to standard inhaled therapies. Follow-up durations were limited in many studies, especially for allergic rhinitis. Data show patterns related to what was studied, but the long-term effects are not fully established, and research is ongoing to better characterize long-term outcomes.

Key Studies & References

  1. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis
  2. Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis

Frequently Asked Questions (FAQ)

Common questions about Asmont (FAQ)


Q: Is Asmont a type of steroid?

Asmont is classified as a Leukotriene Receptor Antagonist (LTRA). Official documents describe its action as blocking leukotrienes, which are inflammatory chemicals, through a specific receptor. This is a different pharmacological mechanism from that of corticosteroids (steroids). Regulatory warnings also note that Asmont is not indicated to replace inhaled or oral corticosteroids abruptly.


Q: Can Asmont affect my mood or cause anxiety?

Official regulatory warnings emphasize the risk of serious neuropsychiatric events associated with the medicine. Reported events include anxiety, agitation, depression, dream abnormalities, and, rarely, suicidal thoughts or behavior. Regulatory documents indicate that patients and caregivers should note and monitor for these changes.


Q: Is it true that Asmont has been studied for other uses?

The official labeling provides specific therapeutic indications for which the medicine is approved, which are asthma, exercise-induced bronchoconstriction (EIB), and allergic rhinitis. Regulatory documents do not address or endorse any use outside of these approved indications.


Q: Does Asmont have an impact on blood pressure?

Regulatory documents list a variety of possible side effects by frequency. Changes in blood pressure (hypertension or hypotension) are not listed among the common or very common adverse reactions documented in the official product information.


Q: What are some less common but important side effects of Asmont?

Official documents highlight rare but serious systemic reactions that have been reported, including cases of hepatitis and vasculitis consistent with Churg-Strauss syndrome (a rare disorder involving inflammation of blood vessel walls). The product information also notes uncommon to very rare events like aggression, sleep disturbances, and dizziness.


Q: Can I take Asmont if I am pregnant or planning to become pregnant?

Available data from published studies have not established a drug-associated risk of major birth defects during pregnancy. Regulatory sources note that the drug is recommended for use during pregnancy only if clearly needed, and official information confirms it passes into breast milk.


Q: What age group is Asmont most commonly prescribed to?

The official labeling outlines approved use for children as young as 6 months for perennial allergic rhinitis, with specific dosage forms (oral granules, chewable tablets) designed for different pediatric age groups. The medicine is approved for use in both pediatric populations and in adults.


Q: How quickly is Asmont expected to start working for most people?

Official documents indicate that the therapeutic effect of the medicine on asthma control parameters occurs within one day of administration. However, this medicine is intended for chronic, preventative use, not for immediate relief of an acute event.


Q: Can Asmont cause weight gain?

Weight gain is not listed in the common or very common adverse reactions reported in regulatory documentation for this medicine.


Q: Does Asmont affect sleep or cause insomnia?

Sleep disturbances, including insomnia and dream abnormalities, are listed as side effects reported in official documentation. These are generally classified in the less common categories of adverse reactions.


Q: Is there a generic version of Asmont available?

The active ingredient in Asmont is Montelukast (as Montelukast Sodium). Montelukast is available as a generic medicine, with regulatory bodies having approved generic versions of the original brand name product.


Q: How is Asmont different from similar medicines used for the same condition?

Official documentation classifies Asmont as a Leukotriene Receptor Antagonist (LTRA). This mechanism specifically blocks the action of leukotrienes, distinguishing its action from classes like inhaled corticosteroids or fast-acting bronchodilators used for the same conditions.


Q: What if I take Asmont at a slightly different time each day?

For asthma, it is typically taken once daily in the evening. The official labeling states that the drug's effect is similar whether it is dosed in the morning or evening. For allergic rhinitis, the administration time may be individualized to suit patient needs.


Q: Are there any restrictions on driving while using Asmont?

Regulatory documents advise that the medicine is not expected to affect the ability to drive or operate machinery. However, due to rare reports of side effects such as dizziness and somnolence (drowsiness), patient awareness of individual response is recommended.


Q: Why is Asmont sometimes prescribed alongside other medications?

Official labeling describes that Asmont can be added to a patient's existing treatment regimen. Clinical studies noted that it provided additional clinical benefit to patients already treated with inhaled corticosteroids or other therapies.


Q: Is Asmont known to interact with herbal supplements?

Standard regulatory interaction tables do not typically include herbal supplements. Official product information advises that the use of any co-administered medicine or product should be noted by a healthcare professional.


Q: Do I need to change my diet while taking Asmont?

Regulatory documents state that film-coated tablets and chewable tablets can be administered with or without food. There are no specific dietary restrictions or necessary dietary changes mandated by the official labeling for most forms.


Q: Does alcohol make Asmont less effective?

The official product information does not list a direct pharmacokinetic interaction between alcohol and Montelukast that reduces the drug's effectiveness. However, regulatory warnings note that liver problems have been reported, often in people with other risk factors such as alcohol use.


Q: Is Asmont available in an injectable form?

Official documents list the available dosage forms as film-coated tablets, chewable tablets, and oral granules. There is no injectable formulation of Asmont listed in the regulatory product information.


Q: Why do official documents mention specific populations regarding Asmont's safety?

Regulatory documents mention specific populations (e.g., pediatric, renal/hepatic impaired) to outline conditions where safety and effectiveness have been established. This ensures the drug is used appropriately and that clinicians are aware of populations requiring specific monitoring for known risks.


Q: What are the signs that Asmont is working for me?

The clinical studies section describes outcomes measured in research, which include changes in lung function measures (like FEV1) and improvements in patient-reported symptom scores and quality of life metrics. These are the ways effectiveness was assessed in official trials.


Q: Can I take cold and flu medicines while using Asmont?

Official interaction studies suggest that Asmont does not significantly alter the action of many common co-administered medicines. Regulatory documents advise that the use of any co-administered medicine, including over-the-counter products, should be noted by a healthcare professional.


Q: Does Asmont interact with birth control pills?

Official drug interaction studies showed that the recommended dose of Montelukast did not have clinically important effects on the pharmacokinetics of oral contraceptives (birth control pills).


Q: What is the maximum duration for which Asmont can be used?

Asmont is officially indicated for the chronic treatment and prophylaxis of asthma and allergic rhinitis. While some research summaries describe studies of one year or less, the drug is authorized for long-term daily use as part of a chronic management plan.


Q: Are there any specific laboratory tests required when taking Asmont?

Although the drug has been associated with changes in liver enzymes and, rarely, eosinophilic conditions, routine laboratory monitoring tests are not explicitly required by the regulatory labeling for all patients.


Q: Does Asmont interact with dairy products?

The film-coated tablets and chewable tablets can be taken with or without food. The oral granules form can be mixed with formula or breast milk. These facts indicate that dairy products, in general, are not restricted.


Q: How should I store my Asmont medication?

Official instructions state the medicine must be stored below 30 C and be protected from both light and moisture. It should be kept in the original package and out of the sight and reach of children.


Q: Is Asmont known to cause issues with teeth or gums?

Official regulatory documents list adverse reactions affecting body systems. Dental or gum issues are not listed in the common or very common adverse reactions reported in the product information.


Q: What are the common misunderstandings about how Asmont should be used?

The most emphasized caution in official documents is that the medicine is not indicated for the reversal of bronchospasm during acute asthma attacks. It is a preventative medication and should not be used as a quick-relief or rescue medicine.


Q: What is the difference between the brand name Asmont and its generic name?

Asmont is a brand name. The official generic name for the active ingredient is Montelukast (as Montelukast Sodium). Regulatory authorities consider generic versions to contain the same active ingredient and be therapeutically equivalent to the brand name product.

How should Asmont be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and handling Asmont (montelukast) to ensure stability and safety.

Storage Component Requirement
Temperature Store below 30 C.
Protection Must be protected from light and moisture.
Container Keep in the original package or outer carton.
Child Safety Must be kept out of the sight and reach of children.

Montelukast oral granules have strict stability rules: the sachet must not be opened until ready to use, and the full dose must be administered within 15 minutes of opening or mixing with food. Any mixed, unused dose must be discarded immediately and must not be stored for later use. Final disposal of expired or unused product must be completed in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asmont found in:

A-Z Index: